LUNG ADENOCARCINOMAS. CLINICOPATHOLOGICAL STUDY WITH RESPECT TO THE UPCOMING NEW CLASSIFICATION AND EGFR-KRAS MUTATION ANALYSIS IMPLICATIONS. First author:

Slides:



Advertisements
Similar presentations
Zeroing in on Non-Small Cell Lung Cancer: Integrating Targeted Therapies into Practice.
Advertisements

Treatment in Advanced Non-Small Cell Lung Cancer.
Carolina Breast Cancer Study: Breast cancer subtypes and race Robert Millikan University of North Carolina Chapel Hill, NC.
EGFR Mutation Testing From the Pathologist’s Point of View
Is the BRAF V600E mutation useful as a predictor of preoperative risk in papillary thyroid cancer? The American Journal of Surgery.
Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR.
Comparison of Serum Human Epididymis Protein 4 with Cancer Antigen 125 as a Tumor Marker in Patients with Malignant and Nonmalignant Diseases J.M. Escudero,
G.Liguori,G.Pirozzi^, I. Forte, G.Botti, R.Franco, A.La Rocca*, G.Rocco* Istituto Nazionale Tumori Napoli Dip.Anatomia Patologica; Dip.Onc.Sperimentale^;
Slides last updated: October There are two main types of lung cancer 1 1.Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review,
Statistics about unknown primary tumors Riccardo Capocaccia National Centre for Epidemiology, Surveillance and Health Promotion Istituto Superiore di Sanità,
Lung Cancer Molecular Pathology of Cancer Boot Camp January 4, 2012 Jennifer Rider, ScD.
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain.
First author: Roman Adina Co-author: Andone Sebastian
INCREASED EXPRESSION OF PROTEIN KINASE CK2  SUBUNIT IN HUMAN GASTRIC CARCINOMA Kai-Yuan Lin 1 and Yih-Huei Uen 1,2,3 1 Department of Medical Research,
Clinicopathologic Features of EML4-ALK Mutant Lung Cancer Shaw AT et al. ASCO 2009; Abstract (Poster)
Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.
Annals of Oncology 23: 298–304, 2012 종양혈액내과 R4 김태영 / prof. 김시영.
Lung cancer Gene Kukuy, MD Cardiothoracic Surgery.
Sex-specific trends in lung cancer incidence and survival : a population study of cases 호흡기 내과 R3 조주희 Thorax 2011;66: Camilla M T Sagerup,
Reducing Tobacco Intake Lowers Risk of Lung Cancer in Heavy Smokers Slideset on: Godtfredsen NS, Prescott E, Osler M. Effect of smoking reduction on lung.
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
EXPRESSION OF ABERRANT p53 PROTEIN IN GASTRIC CANCER
Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer  Anne S. Tsao, MD, Xi Ming Tang, MD, PhD, Bradley Sabloff, MD,
Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma  Zoltan Lohinai, MD, Mir Alireza Hoda, MD,
Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,
Approach to the Ground-Glass Nodule
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Prognosis of younger patients in non-small cell lung cancer
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Approximately 85% of lung cancers are classified as non-small cell lung cancer (NSCLC); of these, adenocarcinoma accounts for 50% of cases, and squamous.
The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer
Molecular pathology of non-small cell lung cancer
A Novel Classification of MUC1 Expression Is Correlated with Tumor Differentiation and Postoperative Prognosis in Non–Small Cell Lung Cancer  Shinjiro.
Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.
Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm  Heounjeong Go, MD, PhD, Dong-Wan Kim,
Bronchioloalveolar Carcinoma (Lepidic Growth) Component Is a More Useful Prognostic Factor than Lymph Node Metastasis  Yoichi Anami, MD, Tatsuo Iijima,
EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy  Michele.
The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.
Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 
Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma  Zoltan Lohinai, MD, Mir Alireza Hoda, MD,
Cigarette Smoking Associated With Lung Adenocarcinoma In Situ in a Large Case- Control Study (SFBALCS)  Paige M. Bracci, PhD, Jennette Sison, MPH, Helen.
Tumor histology predicts mediastinal nodal status and may be used to guide limited lymphadenectomy in patients with clinical stage I non–small cell lung.
Why Do Pathological Stage IA Lung Adenocarcinomas Vary from Prognosis
Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer  Anne S. Tsao, MD, Xi Ming Tang, MD, PhD, Bradley Sabloff, MD,
Iwao Takanami, MD, Ken Takeuchi, MD, Masatoshi Giga, MD 
Published online September 20, 2017 by JAMA Surgery
Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma  Tzu-Hsiu Tsai,
Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry  Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,
Jeffrey Bradley, MD, Issam El Naqa, PhD  Journal of Thoracic Oncology 
A Single Institution-Based Retrospective Study of Surgically Treated Bronchioloalveolar Adenocarcinoma of the Lung: Clinicopathologic Analysis, Molecular.
Clinical courses of patients.
High Incidence of EGFR Mutations in Korean Men Smokers with No Intratumoral Heterogeneity of Lung Adenocarcinomas: Correlation with Histologic Subtypes,
A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER) 
Erratum Journal of Thoracic Oncology
Survival Differences by Gender for Resected Non-small Cell Lung Cancer: A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study 
Prognostic Impact of Node Involvement Pattern in Pulmonary pN1 Squamous Cell Carcinoma Patients  Masayuki Nakao, MD, Junji Yoshida, MD, PhD, Genichiro.
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs  Patrick Micke,
Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for.
Validation of the IASLC/ATS/ERS Lung Adenocarcinoma Classification for Prognosis and Association with EGFR and KRAS Gene Mutations: Analysis of 440 Japanese.
Stromal Macrophage Expressing CD204 is Associated with Tumor Aggressiveness in Lung Adenocarcinoma  Yoichi Ohtaki, MD, Genichiro Ishii, MD, PhD, Kanji.
Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer  Emily Castellanos, MD, Emily Feld, MD, Leora.
Significance of Smoking as a Postoperative Prognostic Factor in Patients with Non- small Cell Lung Cancer  Takeshi Hanagiri, MD, PhD, Kenji Sugio, MD,
Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation 
The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma  Naoki Yanagawa, MD, PhD, Satoshi Shiono, MD, PhD, Masami Abiko,
Trends in survival from metastatic lung cancer in California,
Molecular definitions of lung adenocarcinoma subtypes.
Time Trends of Surgical Outcome in Patients with Non-small Cell Lung Cancer  Takeshi Hanagiri, MD, PhD, Tetsuro Baba, MD, PhD, Tetsuya So, MD, PhD, Manabu.
Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD 
Biomarkers in Early-Stage Non–Small-Cell Lung Cancer: Current Concepts and Future Directions  Mauricio Burotto, MD, Anish Thomas, MD, Deepa Subramaniam,
Presentation transcript:

LUNG ADENOCARCINOMAS. CLINICOPATHOLOGICAL STUDY WITH RESPECT TO THE UPCOMING NEW CLASSIFICATION AND EGFR-KRAS MUTATION ANALYSIS IMPLICATIONS. First author: Andone Sebastian Co-author: Roman Adina Coordinator: Mezei Tibor, MD

Introduction The incidence of lung adenocarcinoma has increased significantly –US > 50% [1] Adenocarcinoma surpassed squamous cell carcinoma in the last few years Recent histopathological and genetic studies provided an extended pathway to research [1]Motoi, Noriko, et al. "Lung adenocarcinoma: modification of the 2004 WHO[..]." The American journal of surgical pathology 32.6 (2008):

2004 WHO Classifcation Introduction Travis et al “International Association for the study of Lung Cancer[..]” Journal of Thoracic Oncology, Volume 6, Number 2 February New proposed classification (WHO 2015)

Current histological types of adenocarcinomas –Mixed subtype –Acinar –Papillary –Solid –Brochioloalveolar Immunohistochemical markers: –CK7, TTF1, Napsin Introduction

Macroscopic aspects of adenocarcinoma

Microscopic aspects of adenocarcinoma [1][2] [3][4] [1] – Acinar [3] – Papillary [2] – Bronchioloalveolar [4] - Solid

Immunohistochemistry stains [1][2] [3][4] [1] – TTF1 [3] – CK7 [2] – TTF1 [4] - CEA

Main purpose: –To review and study adenocarcinoma lung tumors incidence and clinicopathological features Specific purposes: –Obtaining a theoretical basis of EGFR-KRAS mutation implications and the importance of their biologic and therapeutic relevance Objective

140 cases registered at the Pathology Department in the period Evaluation of clinical factors with prognostic value in the diagnosis of adenocarcinoma –Age, gender, tumor size, pathological stage, extent of resection, histological subtype Evaluation of parameters that may suggest possible EGFR or KRAS mutations: –Necrosis, atypical glandular differentiation, mucin growth patterns Material and method

We included the data into two groups: –Low-grade adenocarcinoma –High-grade adenocarcinoma Age and sex distribution Maximal size Location/focality EGFR-KRAS histopathological features Results

Data showed an higher incidence in men (71.40%). Women diagnosed with adenocarcinoma 24,6% ( )  32% ( ) Results

Adenocarcinoma Squamous cell carcinoma

Increased number of women diagnosed with adenocarcinoma than squamous cell carcinoma in the same period. Mean age of diagnosis of adenocarcinoma is 59 years. Age statistical analysis between high-grade- low- grade adenocarcinoma : p=0.18 Results

Maximal size analysis was performed according to histological grade and data distribution to high-grade and low- grade tumors High grade tumors present a higher maximal size distribution (p=0.02) Results

Low grade tumors High grade tumors

Results

Specific EGFR-KRAS histopathological features: Necrosis (70%) Atypical glandular differentiation (35%) Mucin growth patterns (10%) Histological type: 90% of tumors were mixed subtype Results

Possible explanations regarding the increased incidence of adenocarcinoma –Increased incidence of smoking in women –Usage of filter cigarettes [1] –Increased incidence among young adults [2] Discussions [1] Hidemi Ito et al “Nonfilter and filter cigarette consumption [..]” International Journal of Cancer, Volume 128 issue 8, pages 1918–1928, 15 April 2011 [2]Lung Cancer In Young Adults. Bourke W, Milstein D, Giura R, et al.Chest 1992;102(6):

Patients with EGFR mutation were most likely to be never smokers and present stage I disease and had a 90% 3 year-overall survival. Patients with KRAS mutation tumors were more likely to be former/current smokers, present with locally advanced disease and have a 65% 3 year-overall survival. Response to treatment – EGFR mutation – therapy with Tyrosin Kinaze inhibitors – (Erlotininb, Geftinib) In our country, the main therapy includes monoclonal antibodies treatment (Trastuzumab, Bevacizumab), which has proved its efficiency, but is surpassed nowadays in the latest studies by the efficiency of TKI of NSCLC. Discussions Finberg, Karin E., et al. "Mucinous Differentiation Correlates [..]." The Journal of Molecular Diagnostics 9.3 (2007):

Basic conclusions –Increased incidence of diagnosis in women [1] –The incidence of diagnosis in young adults –The upcoming (?) 2015 WHO classification and its possible correlation with genetic mutations –The importance of testing for EGFR-KRAS mutation Conclusions [1] Ronald G.Vincent et al “ The changing histopathology of lung cancer[..]” Cancer, volume 39, Isssue 4 pages June 2006

Novelty and limitations –Complete analysis of clinicopathological features –Statistical analysis based on histological grade comparison –Recent studies evaluation –The limitations of immunohistochemical complete studies –The limitations concerning gene mutation analysis –National Cancer Registry limitations Conclusions